Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock ...

Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 35.6% in the past six months compared with the industry’s decline of 12.3%. The stock has underperformed the sector and the S&P 500 ...

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

While Regeneron stock has rallied by about 45% year-to-date, it still appears reasonably valued, ... What Has Driven Regeneron’s Performance In Recent Years?

Regeneron Pharmaceuticals Inc. closed 55.21% below its 52-week high of $1,211.20, which the company reached on August 27th.

Regeneron reports Q3 EPS of $12.46, up 8% YoY, beating estimates. Revenue rose 11% to $3.72 billion. Key growth from Eylea, Libtayo, and Dupixent drives performance.

This was the stock's fourth consecutive day of gains.

Regeneron (REGN) reported $3.03 billion in revenue for the quarter ended March 2025, representing a year-over-year decline of 3.7%. EPS of $8.22 for the same period compares to $9.55 a year ago ...

REGEN-COV sales, as discussed, will fall from $5.8bn in FY21 to just $681.2m in FY22, but the performance of both Libtayo ... IMO LT investors should continue to buy REGN’s stock every 3-months.

And that's why I'm taking a close look at Regeneron Pharmaceuticals (REGN-0.75%), which is trading at about $830 after touching a recent peak of $847.50. Could this big biotech company be next to ...